Literature DB >> 22190275

Familial antiphospholipid syndrome presenting as bivessel arterial occlusion in a 17-year-old girl.

Marija Jelušić1, Katarina Starčević, Mandica Vidović, Savko Dobrota, Kristina Potočki, Ljiljana Banfić, Branimir Anić.   

Abstract

This article presents a case of a 17-year-old girl with primary antiphospholipid syndrome developing subacute signs of hand and leg ischaemia caused by radiologically verified radial and popliteal artery occlusion. She is successfully treated with a thrombolytic agent (alteplase) and recovers completely. Her laboratory results came positive for all three subtypes of antiphospholipid antibodies. This kind of antiphospholipid syndrome presentation is a very rare entity in itself. Shortly afterwards her mother is diagnosed with primary antiphospholipid syndrome as well. A familial form of antiphospholipid syndrome is suspected. Combination of a familial antiphospholipid syndrome presenting as bivessel arterial thrombosis is a unique case, to the best of our knowledge, never described in the literature before.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190275     DOI: 10.1007/s00296-011-2300-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  11 in total

1.  Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance.

Authors:  N Goel; T L Ortel; D Bali; J P Anderson; I S Gourley; H Smith; C A Morris; M DeSimone; D W Branch; P Ford; D Berdeaux; R A Roubey; D D Kostyu; S F Kingsmore; T Thiel; C Amos; M F Seldin
Journal:  Arthritis Rheum       Date:  1999-02

Review 2.  [Thrombotic manifestations and acute distal ischemia in primary antiphospholipid syndrome in children].

Authors:  F Méchinaud-Lacroix; P Jehan; M A Debré; A M Prieur; J Sizun; J L Harousseau
Journal:  Arch Fr Pediatr       Date:  1992-04

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  Antiphospholipid syndrome presenting as episodic limb ischaemia.

Authors:  R E Evans; M J Dillon; M Alfaham
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

5.  Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings.

Authors:  J M Provenzale; T L Ortel; N B Allen
Journal:  AJR Am J Roentgenol       Date:  1998-02       Impact factor: 3.959

6.  Antiphospholipid syndrome and recurrent thrombosis in children.

Authors:  Y Berkun; S Padeh; J Barash; Y Uziel; L Harel; M Mukamel; S Revel-Vilk; G Kenet
Journal:  Arthritis Rheum       Date:  2006-12-15

Review 7.  Familial lupus and antiphospholipid syndrome.

Authors:  Al Sestak; K M O'Neil
Journal:  Lupus       Date:  2007       Impact factor: 2.911

8.  Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry.

Authors:  Tadej Avcin; Rolando Cimaz; Earl D Silverman; Ricard Cervera; Marco Gattorno; Stella Garay; Yackov Berkun; Flavio R Sztajnbok; Clovis A Silva; Lucia M Campos; Claudia Saad-Magalhaes; Donato Rigante; Angelo Ravelli; Alberto Martini; Blaz Rozman; Pier Luigi Meroni
Journal:  Pediatrics       Date:  2008-10-27       Impact factor: 7.124

Review 9.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 10.  Genetic risk factors of thrombosis in the antiphospholipid syndrome.

Authors:  Jesús Castro-Marrero; Eva Balada; Miquel Vilardell-Tarrés; Josep Ordi-Ros
Journal:  Br J Haematol       Date:  2009-07-30       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.